2. Academic Validation
  3. Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles

Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles

  • Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9. doi: 10.1016/j.bmcl.2010.01.130.
Stephen D Goble 1,  Liping Wang,  K Lulu Howell,  Alka Bansal,  Richard Berger,  Linda Brockunier,  Jerry DiSalvo,  Scott Feighner,  Bart Harper,  Jiafang He,  Amanda Hurley,  Donna Hreniuk,  Emma Parmee,  Michael Robbins,  Gino Salituro,  Anthony Sanfiz,  Eric Streckfuss,  Eloisa Watkins,  Ann E Weber,  Mary Struthers,  Scott D Edmondson
Affiliations

Affiliation

  • 1 Merck Research Laboratories, Rahway, NJ 07065, USA. stephen_goble@merck.com
PMID: 20181479 DOI: 10.1016/j.bmcl.2010.01.130
Abstract

A series of amide derived beta(3)-adrenergic receptor (AR) agonists is described. The discovery and optimization of several series of compounds derived from 1, is used to lay the SAR foundation for second generation beta(3)-AR agonists for the treatment of overactive bladder.

Figures